tresperimus and Chronic-Disease

tresperimus has been researched along with Chronic-Disease* in 2 studies

Reviews

1 review(s) available for tresperimus and Chronic-Disease

ArticleYear
Novel pharmacotherapeutic approaches to prevention and treatment of GVHD.
    Drugs, 2002, Volume: 62, Issue:6

    Acute and chronic graft versus host disease (GVHD) remain the major barriers to successful hematopoietic cell transplantation. The induction of GVHD may be divided into three phases: recipient conditioning;donor T-cell activation; andeffector cells mediating GVHD. This review examines GVHD prevention and treatment using this conceptual model as framework. The various pharmacological agents discussed impact on different phases of the GVHD cascade. For example, keratinocyte growth factor and interleukin (IL)-11 are cytokines that may be useful in disrupting phase I of the GVHD cascade by blocking gastrointestinal tract damage, and lowering serum levels of lipopolysaccharide and tumour necrosis factor (TNF)-alpha. Cyclosporin, tacrolimus (FK-506) and sirolimus (rapamycin) are some of the main agents that disrupt phase II (donor T-cell activation). Mycophenolate mofetil and tresperimus probably act on this phase as well. Other novel drugs that affect phase II are tolerance-induction agents such as CTLA-4 and anti-CD40-ligand monoclonal antibodies, and preliminary results using CTLA-4 monoclonal antibody in GVHD prevention are encouraging. Examples of agents that disrupt phase III are the IL-2 receptor antagonist daclizumab and the anti-TNFalpha monoclonal antibody infliximab. These anti-cytokine antibodies have shown promising results in early studies. The most effective approach to GVHD prevention will probably be a combination regimen where the three phases of the GVHD cascade are disrupted. Once GVHD has occurred, all three phases of the cascade are activated. Developments of combination therapy for treatment of both acute and chronic GVHD are likely to yield better results than monotherapy. The numerous new treatment modalities presented should improve the outlook for patients with acute and chronic GVHD.

    Topics: Acute Disease; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carbamates; Chronic Disease; Combined Modality Therapy; Cyclosporine; Daclizumab; Fibroblast Growth Factor 7; Fibroblast Growth Factors; Graft vs Host Disease; Humans; Immunoglobulin G; Immunosuppressive Agents; Infliximab; Interleukin-11; Mycophenolic Acid; Receptors, Interleukin-2; Sirolimus; T-Lymphocytes; Tacrolimus

2002

Other Studies

1 other study(ies) available for tresperimus and Chronic-Disease

ArticleYear
LF 08-0299 in the prophylaxis and treatment of chronic rejection in a rat aortic allograft model.
    Transplant international : official journal of the European Society for Organ Transplantation, 2000, Volume: 13 Suppl 1

    Chronic rejection is the major cause of late kidney allograft failure. We evaluated the efficacy of LF 08-299 (LF), an analogue of 15-deoxyspergualin, in a rat aortic allograft model of chronic rejection. BN aortic allografts were transplanted to Lew recipients. LF was administered at a dose of 6 mg/kg and 2.5 mg/kg on days 0-20 and 6 mg/kg on days 60-90. CyA was used at a dose of 5 mg/kg on days 0-20. Untreated isografts and allografts were used as controls. Histological changes and immunohistochemistry were monitored sequentially at 8, 12, 16 and 20 weeks. There were no differences in intimal proliferation between LF-treated allografts and untreated or CyA-treated controls. Only a tendency in adventitial infiltration reduction was seen in LF-treated animals. We found a significantly less pronounced reduction in media diameter in LF-treated animals. We concluded that LF 08-0299 is only able to reverse reduction in media thickness in aortic allografts, but not intimal proliferation in this model of chronic rejection.

    Topics: Animals; Aorta; Carbamates; Chronic Disease; Cyclosporine; Dose-Response Relationship, Drug; Graft Rejection; Immunosuppressive Agents; Rats; Rats, Inbred BN; Rats, Inbred Lew; Transplantation, Homologous; Transplantation, Isogeneic

2000